Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan L Fisher

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal for Immunotherapy of Cancer|April 23, 2020
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapyJared E Lopes, Jan L Fisher, Heather L Flick, et al.
Molecular Cancer Therapeutics|May 14, 2017
NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human TumorsClaire Godbersen, Tiffany A Coupet, Amelia M Huehls, et al.
Journal of Chemotherapy (Florence, Italy)|October 8, 2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumoursShodeinde A Coker, Uday B Dandamudi, Andrew P Beelen, et al.
Journal of Immunological Methods|May 10, 2003
Multiparameter precursor analysis of T-cell responses to antigenNadège Bercovici, Alice L Givan, Mary G Waugh, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2018
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survivalLawrence F Kuklinski, Shaofeng Yan, Zhongze Li, et al.
Clinical Immunology (Orlando, Fla.)|July 20, 2005
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patientsTodd S Crocenzi, Christopher P G Tretter, Thomas Schwaab, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2002
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancerLionel D Lewis, Andrew P Beelen, Bernard F Cole, et al.
Pigment Cell & Melanoma Research|January 28, 2014
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032Molly H Jenkins, Shannon M Steinberg, Matthew P Alexander, et al.
The Prostate|January 21, 2006
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF)Thomas Schwaab, Christopher P G Tretter, Jennifer J Gibson, et al.
Plos One|December 11, 2012
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccineBenita Wolf, Adrian Schwarzer, Anik L Côté, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|April 23, 2020
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapyJared E Lopes, Jan L Fisher, Heather L Flick, et al.
Molecular Cancer Therapeutics|May 14, 2017
NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human TumorsClaire Godbersen, Tiffany A Coupet, Amelia M Huehls, et al.
Journal of Chemotherapy (Florence, Italy)|October 8, 2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumoursShodeinde A Coker, Uday B Dandamudi, Andrew P Beelen, et al.
Journal of Immunological Methods|May 10, 2003
Multiparameter precursor analysis of T-cell responses to antigenNadège Bercovici, Alice L Givan, Mary G Waugh, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2018
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survivalLawrence F Kuklinski, Shaofeng Yan, Zhongze Li, et al.
Clinical Immunology (Orlando, Fla.)|July 20, 2005
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patientsTodd S Crocenzi, Christopher P G Tretter, Thomas Schwaab, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2002
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancerLionel D Lewis, Andrew P Beelen, Bernard F Cole, et al.
Pigment Cell & Melanoma Research|January 28, 2014
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032Molly H Jenkins, Shannon M Steinberg, Matthew P Alexander, et al.
The Prostate|January 21, 2006
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF)Thomas Schwaab, Christopher P G Tretter, Jennifer J Gibson, et al.
Plos One|December 11, 2012
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccineBenita Wolf, Adrian Schwarzer, Anik L Côté, et al.
Pageof 3